Swiss Life Sciences Stock News

Roche Holding reported highly positive topline Phase 2 results for its anti obesity drug candidate CT-388 and plans to start Phase 3 trials this quarter. The company also announced a collaboration between Roche Diagnostics and ChemoMetec to develop bioprocess monitoring solutions combining their technologies. Roche Holding (SWX:ROG) is drawing fresh attention after these updates, with its shares at CHF358.7 and a value score of 5. The stock has returned 3.4% over the past week and 8.7% over...

Wondering whether Clariant's share price around CHF 8.25 actually represents good value, or if the market is missing something you should not ignore? The stock has returned 13.2% over the last 7 days and 15.9% over the last 30 days and year to date, although the 1 year, 3 year and 5 year returns of 13.7%, 42.1% and 49.3% declines show a tougher longer term picture. Recent moves come against a backdrop of ongoing interest in chemical producers' portfolio reshaping, cost structures and...

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...

Sandoz Group (SWX:SDZ) is back in focus after Sandoz Canada introduced Enzeevu, its first ophthalmology biosimilar to Eylea, marking an entry into retinal treatments that broadens the group’s biosimilar footprint. See our latest analysis for Sandoz Group. At a share price of CHF61.2, Sandoz Group has posted a 30 day share price return of 6.96% and a 90 day share price return of 12.83%. Its 1 year total shareholder return of 43.19% suggests momentum has been building, with the Enzeevu launch...

Alcon recently launched its PRECISION7 sphere and toric weekly replacement contact lenses in Canada, featuring the ACTIV-FLO System designed to deliver 16 hours of comfort and precise vision through day seven. By combining a one-week replacement schedule with a cost-conscious alternative to daily disposables, PRECISION7 targets a large segment of reusable lens wearers who value both comfort and simplicity. Next, we’ll examine how introducing a weekly replacement lens with the ACTIV-FLO...

In January 2026, Galenica reported group sales of CHF 4,135.6 million for 2025, up from CHF 3,921.1 million a year earlier, reaffirmed improved EBIT guidance of 10–12% and indicated its 2025 dividend should be at least at the prior year’s level. A key element was management’s confirmation that the acquisition of Labor Team is expected to support the targeted EBIT improvement for 2025. Next, we’ll examine how Galenica’s upgraded EBIT outlook, supported by the Labor Team acquisition, shapes...

As the eurozone economy continues its modest recovery, with improved consumer and business confidence, European markets have shown resilience amidst global trade and geopolitical concerns. In this environment, dividend stocks can offer stability and income potential, making them an attractive option for investors looking to navigate the current market dynamics.

Sensirion Holding AG has launched the SCD53, a highly intrinsically stable CO₂ sensor designed to maintain long-term accuracy without manual recalibration or exposure to outdoor air, while offering integrated humidity, temperature and optional pressure compensation in a compact, easily integrated package. By eliminating reliance on automatic baseline calibration and enhancing robustness against dust, vibrations and mechanical stress, the SCD53 directly targets challenging applications such...

Novartis (SWX:NOVN) is back in focus after releasing its fourth quarter and full year 2025 results, pairing high single digit sales growth and a proposed higher dividend with softer guidance for 2026 core operating income. See our latest analysis for Novartis. The recent earnings release, softer 2026 core income guidance and the proposed CHF3.70 dividend appear to be contributing to building momentum. The 30 day share price return of 9.4% and 1 year total shareholder return of 24.7% extend...

As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that are trading below their estimated worth can offer potential opportunities for investors seeking value in an environment where confidence is strengthening and economic recovery continues at a steady pace.

Rieter Holding AG ( VTX:RIEN ) shareholders should be happy to see the share price up 14% in the last month. But that...

The market seemed underwhelmed by the solid earnings posted by Logitech International S.A. ( VTX:LOGN ) recently. Along...

Wondering if UBS Group, at around its recent price of CHF 34.78, still offers value or if most of the easy gains are already behind it? This article walks through the key signals that matter. The stock has seen mixed recent returns, with a 5.4% decline over the last 7 days and an 8.9% decline over the last 30 days. It still shows a 23.4% return over 1 year, about 90.2% over 3 years, and about 189.6% over 5 years. Recent price moves sit against a backdrop of ongoing attention on large global...

Sika (SWX:SIKA) has just opened five new manufacturing sites across the United States, Argentina, Colombia, Bangladesh, and Tanzania, a move that expands its production footprint and supply chain reach in construction materials. See our latest analysis for Sika. Investors appear to be weighing these new plants against a mixed track record, with the 1-day and 7-day share price returns of 2.9% and 5.1% contrasting with a 1-year total shareholder return decline of about 30%. Recent momentum...

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Zuger Kantonalbank (SWX:ZUGER) has just reported its FY 2025 numbers, with second half total revenue of CHF 160.5 million and net income of CHF 60.2 million, while trailing 12 month revenue came in at CHF 328.5 million and net income reached CHF 131.1 million. The bank has seen total revenue move from CHF 315.1 million on a trailing 12 month basis at the end of the second half of 2024 to CHF 328.5 million by the second half of 2025, alongside a net profit margin of 39.9% and a dividend yield...

Why ARYZTA’s latest guidance is back in focus ARYZTA (SWX:ARYN) drew fresh attention after its 2025 sales and trading statement call on 22 January, alongside new earnings guidance for 2026 that points to revenue growth and improved performance for the year. For you as an investor, that combination of an updated outlook and a recent company communication creates a new reference point for reassessing ARYZTA’s current valuation, recent share price moves and the risks around its 2026 targets. See...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...

Forbo Holding AG has announced that Heinz Hössli will become Chief Financial Officer and Executive Board member on 1 July 2026, succeeding interim CFO Peter Germann, who will retire. This appointment brings in a finance leader with broad international industrial and automation experience, reinforcing Forbo’s leadership bench for its ongoing transformation plans. We’ll now examine how the arrival of an internationally experienced CFO could influence Forbo Holding’s broader investment...

In January 2026, BlackRock and Partners Group launched a first-of-its-kind multi-alternatives separately managed account on the Morgan Stanley wealth platform, giving advisors streamlined access to diversified private equity, private credit, and real assets through three outcome-aligned strategies. This structure is designed to remove common barriers to private market access by consolidating seven evergreen private market funds into a single, operationally simple solution for financial...

Julius Bär Gruppe has reported full-year 2025 results showing net income of CHF 763.7 million versus CHF 1,022.1 million a year earlier, alongside an unchanged proposed ordinary dividend of CHF 2.60 per share and board changes including Juerg Hunziker’s appointment as Vice Chairman. The combination of lower headline profit driven by one-off items and credit write-downs, a steady dividend proposal, and governance refresh underpins an evolving investment story focused on underlying...

It is hard to get excited after looking at Tecan Group's (VTX:TECN) recent performance, when its stock has declined...

Context for Alcon’s recent share performance Alcon (SWX:ALC) has caught investor attention after a period of mixed share performance, with the stock declining over the past month while posting a small gain in the past 3 months. That short term pattern sits alongside a weaker year to date and 1 year total return, prompting some investors to reassess how the eye care group’s current fundamentals and valuation line up with their expectations. See our latest analysis for Alcon. With the share...

Cosmo Pharmaceuticals N.V. recently completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding shares, with Capital Group’s SMALLCAP World Fund, using only existing treasury stock and therefore avoiding dilution for current shareholders. The deal brings a globally recognized institutional investor into Cosmo’s shareholder base while providing additional financial flexibility to support its MedTech AI, dermatology, gastroenterology, and CDMO...